A funded Gilead partnership and multiple clinical starts support an asymmetric thesis, but an ongoing research cash burn, warrant overhang and binary trial outcomes keep the equity speculative. Base fair value is a model estimate, not an assured cash floor.
rNPV construction and limits. Peak-sales envelopes, margins, ramp factors, approval probabilities and 16% discount rate are analyst assumptions, not company guidance or validated epidemiology. The 40% HSV US profit share also commits Assembly to 40% of US development costs; modeled HSV margin is net profit, not a gross royalty. The $75m fee is counted once in liquidity, with no milestones embedded in program NPVs. Cash is dated June 30, while the 20.36m economic share denominator is later; ~$11m of July warrant exercise proceeds is omitted, a conservative ~$0.54/share sensitivity. The $25.2m liabilities reserve includes $16.3m deferred revenue, which is not immediate cash debt, and may overlap with modeled burn. Class B warrants are cancelled only if at least $75m non-dilutive collaboration capital is publicly announced by November 15, 2026; cancellation is not assumed. Other warrants can dilute a rerating. Independent check: applying PRTA's 4.37x EV/forward revenue to ASMB's vendor-implied ~$54.3m forward collaboration revenue, then adding the modeled $332.6m cash bridge, gives ~$28.0/share, 11.3% below the $31.58 rNPV. This check is weak because collaboration recognition is not product demand; ARVN's negative EV makes its EV multiple unusable. Implied ASMB rNPV EV/TTM collaboration revenue is (~$643m equity value − $332.6m cash bridge) / $74.85m ≈ 4.15x. Sensitivity: −10 percentage points in HSV success lowers FV ~$2.75/share; −10 points in ABI-6250 lowers it ~$1.98; 10% more shares with no cash proceeds lowers FV to ~$28.71. A $75m fee miss alone lowers FV ~$3.68. Dated September 21 H.C. Wainwright $50 and September 1 UBS $52 targets are materially above this model, likely reflecting stronger pipeline assumptions; they are not inputs. Scenarios are path outcomes, not a guaranteed cash floor. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Cash and securities | $320.4m reported 2026-06-30 / 20.36m economic shares; July exercise proceeds excluded conservatively | +15.74 |
| Scheduled Gilead fee | $75m Gilead extension fee scheduled Q4 2026 / 20.36m shares; conditional on collection | +3.68 |
| Interim cash use and liabilities | −$37.6m H2 burn proxy (H1 run-rate) and −$25.2m June liabilities / 20.36m shares; conservative because $16.3m deferred revenue is non-cash | -3.08 |
| HSV program rNPV | $1.0bn modeled US peak sales × 30% net margin × 40% Assembly profit share / (16% discount rate − 3% growth) × 0.867 commercialization ramp ≈ $800m success value; ×30% success ×0.70 launch discount / shares | +8.25 |
| ABI-6250 HDV/PBC/PSC rNPV | $300m modeled peak franchise sales ×40% margin / (16%−3%) ×0.704 ramp ≈ $650m success value; ×25% success ×0.62 launch discount / shares | +4.95 |
| Other pipeline / platform rNPV | $200m modeled peak sales ×35% margin / (16%−3%) ×0.743 ramp ≈ $400m success value; ×20% success ×0.52 launch discount / shares | +2.04 |
| Base fair value | 15.74 + 3.68 − 3.08 + 8.25 + 4.95 + 2.04 = 31.58 (rounded $/share components) | +31.58 |
| USD millions | FY2024 | FY2025 | FY2026E* | FY2027E |
|---|---|---|---|---|
| Collaboration revenue | 28.52 | 72.30 | N/D — no guidance | N/D — no guidance |
| Net income / (loss) | −40.18 | −6.12 | N/D — no guidance | N/D — no guidance |
| Operating cash flow | −51.12 | −41.09 | −75.17* | N/D — trial costs uncertain |
| Free cash flow (OCF less capex) | −51.15 | −41.16 | ~−75.2* | N/D — trial costs uncertain |
| Cash and securities, period end | 112.08 | 248.11 | ~357.8* | N/D — financing and costs uncertain |
| Metric | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
| Gilead collaboration revenue | 10.79 | 42.47 | 8.21 | 13.37 |
| Gross margin | N/D — no COGS | N/D — no COGS | N/D — no COGS | N/D — no COGS |
| Operating expenses | 21.67 | 22.67 | 19.58 | 19.72 |
| Net income / (loss) | −9.20 | +22.09 | −9.08 | −3.86 |
| Operating cash flow | −15.13 | +14.24 | −22.10 | −15.49 |
| Cash and securities, period end | 232.56 | 248.11 | 226.60 | 320.36 |
Business model and pipeline
| Program | Stage at 2026-10-25 | Next disclosed step |
|---|---|---|
| GS-1179 HSV | Partner-controlled; Phase 2 planned | Initiation by 2026-12-31 |
| ABI-6250 HDV | Phase 1a completed | Phase 2 start by 2026-12-31 |
| ABI-6250 PBC/PSC | Pre-Phase 2 | Phase 2 start in Q1 2027 |
| ABI-4334 and platform | Earlier stage | Progress updates; timing not firm |
Risk grid
SWOT
- +$320.4m June cash and securities.
- +Gilead HSV collaboration validates external interest.
- +$75m extension payment scheduled in Q4.
- +H1 operating cash use improved year over year.
- −No approved medicine or product sales.
- −Economic shares more than doubled year over year.
- −Related-party revenue is milestone driven.
- −A large warrant stack can dilute upside.
- →GS-1179 Phase 2 expected by year end.
- →ABI-6250 HDV Phase 2 expected by year end.
- →PBC/PSC expansion expected Q1 2027.
- →AASLD presentation may clarify target engagement.
- !Phase 2 efficacy can fail despite Phase 1 safety.
- !Partner timing can slip.
- !Runway shrinks as trials expand.
- !Capital markets can discount warrant overhang.
Investment summary
- Gilead pays the fee, partner and owned trials start, and initial clinical signals lift probability-adjusted pipeline value.
- The cash runway finances scheduled starts; a $31.58 rNPV reflects remaining clinical and financing uncertainty.
- Delays or poor data consume cash while warrants limit per-share recovery; $12.50 is possible despite June liquidity.
Sources and timing. Q2 2026 Form 10-Q · Q2 2026 company results · September HSV profit-share election · FY2025 Form 10-K · October 23 quote · October 23 price confirmation · Short interest, September 30 · Analyst targets, dated October 20 page . Price as of 2026-10-23 close; balance-sheet data as of 2026-06-30 unless stated. All program NPVs and scenarios are analyst estimates. ⚠️ Not investment advice. · October 5 AASLD issuer release · Arvinas Q2 release · Ocular Therapeutix 10-Q · Prothena 10-Q · Q3 2025 Form 10-Q · Q1 2026 Form 10-Q · PRTA multiples · ARVN multiples · OCUL multiples · ASMB multiples · March 2026 shelf registration · Reported insider transactions · Dated analyst targets